{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:02:49Z","timestamp":1705276969632},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.vaccine.2004.08.037","type":"journal-article","created":{"date-parts":[[2004,10,6]],"date-time":"2004-10-06T14:44:56Z","timestamp":1097073896000},"page":"1399-1407","source":"Crossref","is-referenced-by-count":8,"title":["Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides"],"prefix":"10.1016","volume":"23","author":[{"given":"Guillaume","family":"Belliard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Hurtrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard A.","family":"P. Lafont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Monceaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Roques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Desgranges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie","family":"Aubertin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger Le","family":"Grand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylviane","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2004.08.037_bib1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nm0996-960","article-title":"HIV-1 Tat protein as a potential AIDS vaccine","volume":"1","author":"Goldstein","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2004.08.037_bib2","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.96.15.8324","article-title":"Tat as one key to HIV-induced immune pathogenesis and Tat toxoid as an important component of a vaccine","volume":"96","author":"Gallo","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2004.08.037_bib3","first-page":"23","article-title":"Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus","author":"Ensoli","year":"2000","journal-title":"AIDS Clin Rev (Volberding and Jacobson eds.)"},{"key":"10.1016\/j.vaccine.2004.08.037_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1054-3589(00)48007-5","article-title":"Tat as a transcriptional activator and a potential therapeutic target for HIV-1","volume":"48","author":"Gatignol","year":"2000","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1054-3589(00)48008-7","article-title":"From the outside in: extracellular activities of HIV Tat","volume":"48","author":"Noonan","year":"2000","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/9488","article-title":"Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine","volume":"5","author":"Cafaro","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2004.08.037_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1034\/j.1600-0684.2000.290313.x","article-title":"SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine","volume":"29","author":"Cafaro","year":"2000","journal-title":"J Med Primatol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib8","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/S0264-410X(00)00085-2","article-title":"Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian\/human immunodeficiency virus (SHIV33)","volume":"18","author":"Goldstein","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.037_bib9","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1073\/pnas.070049797","article-title":"Vaccination with tat toxoid attenuates disease in simian\/HIV-challenged macaques","volume":"97","author":"Pauza","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2004.08.037_bib10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1089\/104454902760330174","article-title":"Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses","volume":"21","author":"Richardson","year":"2002","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib11","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1128\/JVI.76.8.3800-3809.2002","article-title":"Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein","volume":"76","author":"Silvera","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/35036559","article-title":"Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia","volume":"407","author":"Allen","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2004.08.037_bib13","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1016\/S0264-410X(01)00002-0","article-title":"Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian\/human immunodeficiency virus (SHIV89.6P)","volume":"19","author":"Cafaro","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.037_bib14","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1128\/JVI.76.8.4108-4112.2002","article-title":"Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication","volume":"76","author":"Allen","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/104454902760330183","article-title":"Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08","volume":"21","author":"Verrier","year":"2002","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib16","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1016\/S0264-410X(03)00233-0","article-title":"Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals","volume":"21","author":"Belliard","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.037_bib17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0753-3322(97)82330-X","article-title":"B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains","volume":"51","author":"Tahtinen","year":"1997","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2004.08.037_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00042560-199912010-00007","article-title":"Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma","volume":"22","author":"Demirhan","year":"1999","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.vaccine.2004.08.037_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0198-8859(99)00052-X","article-title":"The human uniqueness of HIV: innate immunity and the viral Tat protein","volume":"60","author":"Rodman","year":"1999","journal-title":"Hum Immunol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1386-6532(00)00189-X","article-title":"Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients","volume":"21","author":"Re","year":"2001","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib21","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1016\/S0264-410X(03)00295-0","article-title":"Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA","volume":"21","author":"Marinaro","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2004.08.037_bib22","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1128\/JVI.77.5.3157-3166.2003","article-title":"Tat-neutralizing antibodies in vaccinated macaques","volume":"77","author":"Tikhonov","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib23","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1128\/JVI.78.7.3792-3796.2004","article-title":"Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen","volume":"78","author":"Moreau","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib24","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/IAI.70.6.3012-3019.2002","article-title":"The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4+ T cells and secrete gamma interferon after coapplication onto bare skin","volume":"70","author":"Beignon","year":"2002","journal-title":"Infect Immunity"},{"key":"10.1016\/j.vaccine.2004.08.037_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/viro.1996.0486","article-title":"High viral load and CD4 lymphopenia in rhesus and cynomolgus macaques infected by a chimeric primate lentivirus constructed using the env, rev, tat and vpu genes from HIV-1 LAI","volume":"223","author":"Dunn","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2004.08.037_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1034\/j.1600-0684.2000.290305.x","article-title":"Early changes in peripheral blood T cells during primary infection of rhesus macaques with pathogenic SIV","volume":"29","author":"Estaquier","year":"2000","journal-title":"J Med Primatol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/104454902760330138","article-title":"HIV-1 Tat-based vaccines: from basic science to clinical trials","volume":"21","author":"Fanales-Belasio","year":"2002","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib28","first-page":"282","article-title":"Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat Toxo\u00efd as an HIV-1 vaccine","volume":"1","author":"Zagury","year":"1998","journal-title":"J Hum Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0753-3322(02)00327-X","article-title":"Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection","volume":"57","author":"Richardson","year":"2003","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2004.08.037_bib30","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1073\/pnas.98.4.1781","article-title":"The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals","volume":"98","author":"Addo","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2004.08.037_bib31","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/(SICI)1521-4141(200004)30:4<1120::AID-IMMU1120>3.0.CO;2-4","article-title":"Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR","volume":"30","author":"Tosi","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib32","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1099\/vir.0.80365-0","article-title":"Important B cell epitopes for Tat-neutralisation in the serum samples of humans and different animal species immunised with Tat protein or Tat peptides","volume":"85","author":"Moreau","year":"2004","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1128\/JVI.77.2.1049-1058.2003","article-title":"Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine","volume":"77","author":"Voss","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2004.08.037_bib34","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1073\/pnas.95.7.3851","article-title":"Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.","volume":"95","author":"Zagury","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2004.08.037_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/104454902760330147","article-title":"Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine","volume":"21","author":"Gallo","year":"2002","journal-title":"DNA Cell Biol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04006607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X04006607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T15:00:45Z","timestamp":1705244445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X04006607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0264410X04006607"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2004.08.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}